TY-302

N/A

Report date: 2025/07/02 17:51:31
NME

Base Information

Drug NameTY-302
Drug Alias Name氘代哌柏西利TY-302
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Deuterated drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms, Castration-Resistant +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTYK Medicines Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTYK Medicines IncZhengzhou Taiji Hongnuo Medicine Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms, Castration-Resistant +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A